Abstract:Abstract Background The motif RXDLXXL-based nanoprobes allow specific imaging of integrin α v β 6 , a protein overexpressed during tumorigenesis and tumor progression of various tumors. We applied a novel RXDLXXL-coupled cyclic arginine-glycine-aspartate (RGD) nonapeptide conjugated with ultrasmall superparamagnetic iron oxide nanoparticles (referred to as cFK-9-USPIO) for the application of integrin α v β 6 -targeted magnetic resonance (MR) molecular imaging for breast cancer. Methods A novel MR-targeted nanoprobe, cFK-9-USPIO, was synthesized by conjugating integrin α v β 6 -targeted peptide cFK-9 to N-amino (−NH2)-modified USPIO nanoparticles via a dehydration esterification reaction. Integrin α v β 6 -positive mouse breast cancer (4 T1) and integrin α v β 6 negative human embryonic kidney 293 (HEK293) cell lines were incubated with cFK-9-AbFlour 647 (blocking group) or cFK-9-USPIO (experimental group), and subsequently imaged using laser scanning confocal microscopy (LSCM) and 3.0 Tesla magnetic resonance imaging (MRI) system. The affinity of cFK-9 targeting α v β 6 was analyzed by calculating the mean fluorescent intensity in cells, and the nanoparticle targeting effect was measured by the reduction of T2 values in an in vitro MRI. The in vivo MRI capability of cFK-9-USPIO was investigated in 4 T1 xenograft mouse models. Binding of the targeted nanoparticles to α v β 6 -positive 4 T1 tumors was determined by ex vivo histopathology. Results In vitro laser scanning confocal microscopy (LSCM) imaging showed that the difference in fluorescence intensity between the targeting and blocking groups of 4 T1 cells was significantly greater than that in HEK293 cells ( P < 0.05). The in vitro MRI demonstrated a more remarkable T2 reduction in 4 T1 cells than in HEK293 cells ( P < 0.001). The in vivo MRI of 4 T1 xenograft tumor-bearing nude mice showed significant T2 reduction in tumors compared to controls. Prussian blue staining further confirmed that α v β 6 integrin-targeted nanoparticles were specifically accumulated in 4 T1 tumors and notably fewer nanoparticles were detected in 4 T1 tumors of mice injected with control USPIO and HEK293 tumors of mice administered cFK-9-USPIO. Conclusions Integrin α v β 6 -targeted nanoparticles have great potential for use in the detection of α v β 6 -overexpressed breast cancer with MR molecular imaging.

Molecular Imaging Probes for Integrin Α_vβ_3

Molecular Imaging of Integrin Αvβ6 Expression in Living Subjects.

Molecular Imaging Of Integrin Alpha(V)Beta(6) Expression In Living Subjects

Specific detection of integrin αvβ3 by light-up bioprobe with aggregation-induced emission characteristics.

Specific Detection Of Integrin Alpha(V)Beta(3) By Light-Up Bioprobe With Aggregation-Induced Emission Characteristics

A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin αvβ3 with magnetic probes.

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

A Lipopeptide-Based Αvβ3 Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis

Design and Development on Tumor Imaging of Nonpeptide Small Molecular Antagonists of Integrin Αⅴβ3

Imaging integrin αvβ3 positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake

Synthesis and Evaluation of a Novel BODIPY Fluorescent Probe Targeting Integrin Αvβ3 for Cancer Diagnosis

99Mtc-3P-rgd2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin Αvβ3-Targeted Therapy

A Cystine Knot Peptide Targeting Integrin αvβ6 for Photoacoustic and Fluorescence Imaging of Tumors in Living Subjects

Screening a DNA Aptamer Specifically Targeting Integrin β3 and Partially Inhibiting Tumor Cell Migration

Integrin targeted delivery of radiotherapeutics.

Integrin-targeting Block Copolymer Probes for Two-Photon Fluorescence Bioimaging.

Novel Linear Peptides with High Affinity to Αvβ3 Integrin for Precise Tumor Identification.

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model